ArticleJournal of inflammation (London, England)2011
The effect of the CCR5-delta32 deletion on global gene expression considering immune response and inflammation.
Article in Journal of inflammation (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection.Molecular medicine (Cambridge, Mass.) · 2012Trial
- Distribution of CCR5-Δ32 and HLA-B*57:01 alleles in HIV-seropositive and HIV-exposed seronegative Peruvian individuals.Human genome variation · 2025Article
- Whole-Blood Longitudinal Molecular Profiling Maps the Road of Graft Versus Host Disease (GVHD).Cancers · 2025Article
- C-C chemokine receptor 5 and acute graft-versus-host disease.Immunity, inflammation and disease · 2022Review
- Detection of CCR5Δ32 Mutant Alleles in Heterogeneous Cell Mixtures Using Droplet Digital PCR.Frontiers in molecular biosciences · 2022Review
- CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population.Frontiers in immunology · 2021Review
- High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients.EBioMedicine · 2020Article
- Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.Virus research · 2020Review
- Combined Effect of HPV and Several Gene SNPs in Laryngeal Cancer.Medicina (Kaunas, Lithuania) · 2020Article
- LRG1 promotes proliferation and inhibits apoptosis in colorectal cancer cells via RUNX1 activation.PloS one · 2017Article
- In vitro immunological effects of blocking CCR5 on T cells.Inflammation · 2015Article
- Prophylaxis of acute graft-versus-host disease by CCR5 blockade combined with cyclosporine A in a murine model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2015Article
- LRG1 is an independent prognostic factor for endometrial carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV.Viral immunology · 2013Article
- Prospects for treatment of latent HIV.Clinical pharmacology and therapeutics · 2013Review
- Effects of small intestinal submucosa (SIS) on the murine innate immune microenvironment induced by heat-killed Staphylococcus aureus.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe natural function of the C-C chemokine receptor type 5 (CCR5) is poorly understood. A 32 base pair deletion in the CCR5 gene (CCR5-delta32) located on chromosome 3 results in a non-functional protein. It is supposed that this deletion causes an alteration in T-cell response to inflammation. For example, the presence of the CCR5-delta32 allele in recipients of allografts constitutes as an independent and protective factor associated with a decreased risk of graft-versus-host disease (GVHD) and graft rejection. However, the mechanism of this beneficial effect of the deletion regarding GVHD is unknown. In this survey we searched for a CCR5-delta32 associated regulation of critical genes involved in the immune response and the development of GVHD.
methodsWe examined CD34+ hematopoietic progenitor cells derived from bone marrow samples from 19 healthy volunteers for the CCR5-delta32 deletion with a genomic PCR using primers flanking the site of the deletion.
results12 individuals were found to be homozygous for CCR5 WT and 7 carried the CCR5-delta32 deletion heterozygously. Global gene expression analysis led to the identification of 11 differentially regulated genes. Six of them are connected with mechanisms of immune response and control: LRG1, CXCR2, CCRL2, CD6, CD7, WD repeat domain, and CD30L.
conclusionsOur data indicate that the CCR5-delta32 mutation may be associated with differential gene expression. Some of these genes are critical for immune response, in the case of CD30L probably protective in terms of GVHD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.